 |
|
|
| |
Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the carnitine transporter OCTN2 and the mitochondrial carnitine shuttle
|
| |
| |
EASL 2024 June 5-8
Xia Wu1, Yen-Wen Chen2, Jiangao Song1, Edward E Cable1, Jeff D Johnson1, Joanne Elliott2, Francisco J Caballero-Camino3,
Xin Chen1, Robert Martin1, Jeffrey W Stebbins1, Jesus M Banales3, Charles A McWherter1
1CymaBay Therapeutics, Inc., Fremont, United States, 2Triple Ring Technologies Inc., Newark, United States, 3Biogipuzkoa Health Research Institute, San Sebastian, Spain
|
| |
|
|
|
|
|
